Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Biomedical Optics Express|November 25, 2015
Effect of recombinant interleukin-12 on murine skin regeneration and cell dynamics using in vivo multimodal microscopyJoanne Li, Andrew J Bower, Vladimir Vainstein, et al.
Plos One|July 21, 2021
Gene expression changes in male and female rhesus macaque 60 days after irradiationMatthäus Majewski, Patrick Ostheim, Zoya Gluzman-Poltorak, et al.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
Acta Haematologica|August 7, 2022
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid LeukemiaBoaz Nachmias, Svetlana Krichevsky, Dvora Filon, et al.
European Journal of Haematology|December 24, 2022
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myelomaOded Shamriz, Elchanan Parnasa, Limor Rubin, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
Annals of Hematology|June 22, 2022
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysisOfir Wolach, Avraham Frisch, Liat Shargian, et al.
Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
Pageof 5